Germany
XO Life, founded in 2021, is a German startup revolutionizing the biotechnology and pharmaceutical industries with its platform, briteβ’. The company addresses a critical gap in healthcare by transforming therapy support into actionable real-world evidence, thus helping pharmaceutical and MedTech companies maintain visibility of their therapies beyond clinical trials.
briteβ’ stands out as a digital meta-platform that bridges pharmaceutical and MedTech manufacturers with their patients throughout the therapy process. Contrary to traditional single-product apps, briteβ’ offers comprehensive support across multiple therapies and manufacturers within a unified application. This approach provides patients with customized medical content and progress tracking, while manufacturers gain invaluable structured data for post-market safety and market access strategies.
With a clientele of over 40 companies, including three leading global pharma giants, XO Life boasts user engagement rates tenfold higher than the digital health sector standard. Their recent β¬4.00M early VC investment, backed by investors such as Fil Rouge Capital, Bayern Kapital, VI Partners, Grazia Equity, and Sandwater, underscores the confidence and potential seen in XO Life's innovative approach.
